165 237

Cited 96 times in

p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming

Authors
 Tetsuya Saito  ;  Yoshinobu Ichimura  ;  Keiko Taguchi  ;  Takafumi Suzuki  ;  Tsunehiro Mizushima  ;  Kenji Takagi  ;  Yuki Hirose  ;  Masayuki Nagahashi  ;  Tetsuro Iso  ;  Toshiaki Fukutomi  ;  Maki Ohishi  ;  Keiko Endo  ;  Takefumi Uemura  ;  Yasumasa Nishito  ;  Shujiro Okuda  ;  Miki Obata  ;  Tsuguka Kouno  ;  Riyo Imamura  ;  Yukio Tada  ;  Rika Obata  ;  Daisuke Yasuda  ;  Kyoko Takahashi  ;  Tsutomu Fujimura  ;  Jingbo Pi  ;  Myung-Shik Lee  ;  Takashi Ueno  ;  Tomoyuki Ohe  ;  Tadahiko Mashino  ;  Toshifumi Wakai  ;  Hirotatsu Kojima  ;  Takayoshi Okabe  ;  Tetsuo Nagano  ;  Hozumi Motohashi  ;  Satoshi Waguri  ;  Tomoyoshi Soga  ;  Masayuki Yamamoto  ;  Keiji Tanaka  ;  Masaaki Komatsu 
Citation
 NATURE COMMUNICATIONS, Vol.7 : 12030, 2016 
Journal Title
 NATURE COMMUNICATIONS 
Issue Date
2016
Abstract
p62/Sqstm1 is a multifunctional protein involved in cell survival, growth and death, that is degraded by autophagy. Amplification of the p62/Sqstm1 gene, and aberrant accumulation and phosphorylation of p62/Sqstm1, have been implicated in tumour development. Herein, we reveal the molecular mechanism of p62/Sqstm1-dependent malignant progression, and suggest that molecular targeting of p62/Sqstm1 represents a potential chemotherapeutic approach against hepatocellular carcinoma (HCC). Phosphorylation of p62/Sqstm1 at Ser349 directs glucose to the glucuronate pathway, and glutamine towards glutathione synthesis through activation of the transcription factor Nrf2. These changes provide HCC cells with tolerance to anti-cancer drugs and proliferation potency. Phosphorylated p62/Sqstm1 accumulates in tumour regions positive for hepatitis C virus (HCV). An inhibitor of phosphorylated p62-dependent Nrf2 activation suppresses the proliferation and anticancer agent tolerance of HCC. Our data indicate that this Nrf2 inhibitor could be used to make cancer cells less resistant to anticancer drugs, especially in HCV-positive HCC patients.
Files in This Item:
T201603549.pdf Download
DOI
10.1038/ncomms12030
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
Yonsei Authors
Lee, Myung Shik(이명식) ORCID logo https://orcid.org/0000-0003-3292-1720
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/151984
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links